{"claimId":"clm_ec_b11-berberine-inflammation","grade":"B","version":0,"status":"current","verdict":"Berberine for inflammation: Grade B at moderate certainty. Meta-analysis of 5 RCTs: berberine supplementation significantly decreased serum C-reactive protein versus control, with no significant heterogeneity between studies. The authors note patients with cardiovascular disease and diabetes may be the groups most likely to benefit; larger confirmatory trials are still needed.","direction":"benefit","magnitude":{"metric":"other","value":null,"unit":"","ci95":null,"humanReadable":"Meta-analysis of 5 RCTs: berberine supplementation significantly decreased serum C-reactive protein versus control, with no significant heterogeneity between studies. The authors note patients with cardiovascular disease and diabetes may be the groups most likely to benefit; larger confirmatory trials are still needed.","baselineAbsoluteRisk":null},"certainty":"moderate","clinicalMeaning":"small_but_potentially_useful","applicability":{"appliesTo":["adults, especially with cardiovascular disease or diabetes"],"doesNotApply":[],"unknown":[]},"safetyQualifiers":["moderate_with_metformin"],"evidenceBundleId":"eb_ec_b11-berberine-inflammation","citations":[{"pmid":"31519292","design":"peer-reviewed"}],"reviewedBy":null,"reviewedAt":"2026-07-16T16:40:57.326Z","dateModified":"2026-07-16T16:40:57.326Z","methodologyVersion":"v1","methodologyDoi":"https://doi.org/10.5281/zenodo.21364236","canonicalUrl":"https://evidencebased.info/interventions/berberine/inflammation","attribution":"Substrate (evidencebased.info), claim clm_ec_b11-berberine-inflammation v0, reviewed 2026-07-16","license":"CC-BY-4.0 proposed; reuse license pending governance ratification","governanceMode":"legacy","governanceStatus":"legacy-unverified","dataSource":"live"}